AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31833569 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice (70 mL, ≤11 mmol nitrate)
Number of subjects: 100
Study 31833569 — intervention group
Group type: COMPARATOR
Intervention: Nitrate-depleted juice (placebo; 0 mmol nitrate)
Number of subjects: 100
Study 28737971 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate (FF; 100 μg)
Number of subjects: 16485
Study 28737971 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilanterol (VI; 25 μg)
Number of subjects: 16485
Study 28737971 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate and Vilanterol (FF/VI)
Number of subjects: 16485
Study 28737971 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16485
Study 27871548 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (group SEV)
Number of subjects: 46
Study 27871548 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane (group ISO)
Number of subjects: 46
Study 27871548 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (in vitro)
Number of subjects: 46
Study 27871548 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane (in vitro)
Number of subjects: 46
Study 24361787 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphadenectomy
Number of subjects: 0
Study 24361787 — intervention group
Group type: COMPARATOR
Intervention: No lymphadenectomy
Number of subjects: 0
Study 24361787 — intervention group
Group type: EXPERIMENTAL
Intervention: Node negative patients (≤65 years)
Number of subjects: 0
Study 24361787 — intervention group
Group type: EXPERIMENTAL
Intervention: Node positive patients (≤65 years)
Number of subjects: 0
Study 24361787 — intervention group
Group type: EXPERIMENTAL
Intervention: Node negative patients (>65 years)
Number of subjects: 0
Study 24361787 — intervention group
Group type: EXPERIMENTAL
Intervention: Node positive patients (>65 years)
Number of subjects: 0
Study 24361787 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity (BMI >30) in older patients
Number of subjects: 0
Study 22526822 — intervention group
Group type: EXPERIMENTAL
Intervention: Difficulty in initiating sleep (DIS)
Number of subjects: 6510
Study 22526822 — intervention group
Group type: EXPERIMENTAL
Intervention: Difficulty in maintaining sleep (DMS)
Number of subjects: 6510
Study 22526822 — intervention group
Group type: EXPERIMENTAL
Intervention: Early morning awakening (EMA)
Number of subjects: 6510
Study 22526822 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-restorative sleep (NRS)
Number of subjects: 6510
Study 22526822 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall insomnia
Number of subjects: 6510
Study 22526822 — intervention group
Group type: EXPERIMENTAL
Intervention: Sociodemographic and clinical correlates
Number of subjects: 6510
Study 22526822 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-related risks
Number of subjects: 6510
Study 22526822 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric disorders
Number of subjects: 6510
Study 20546495 — intervention group
Group type: EXPERIMENTAL
Intervention: Group ZP (fully anatomical technique)
Number of subjects: 30
Study 20546495 — intervention group
Group type: EXPERIMENTAL
Intervention: Group ZC (traditional layering technique)
Number of subjects: 30
Study 20546495 — intervention group
Group type: EXPERIMENTAL
Intervention: Group ZPC (cutback technique)
Number of subjects: 30
Study 18988166 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg intravitreal bevacizumab (IVB group)
Number of subjects: 110
Study 18988166 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 1.25 mg bevacizumab and 2 mg triamcinolone acetonide (IVB+IVT group)
Number of subjects: 110
Study 18988166 — intervention group
Group type: COMPARATOR
Intervention: Macular laser photocoagulation (MPC)
Number of subjects: 110
Study 15965622 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal care from health department clinics
Number of subjects: 1867
Study 15965622 — intervention group
Group type: COMPARATOR
Intervention: Prenatal care from private physicians or HMOs
Number of subjects: 1867
Study 15965622 — intervention group
Group type: COMPARATOR
Intervention: Prenatal care from hospital clinics
Number of subjects: 1867
Study 15965622 — intervention group
Group type: COMPARATOR
Intervention: Prenatal care from other sites
Number of subjects: 1867
Study 15965622 — intervention group
Group type: COMPARATOR
Intervention: Overall population
Number of subjects: 1867
Study 15965622 — intervention group
Group type: COMPARATOR
Intervention: Private prenatal patients compared to health department prenatal clinic patients
Number of subjects: 1867
Study 12059911 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0% sodium hypochlorite associated with 15% EDTAC
Number of subjects: 20
Study 12059911 — intervention group
Group type: COMPARATOR
Intervention: 1.0% sodium hypochlorite alone
Number of subjects: 20
Study 12059911 — intervention group
Group type: COMPARATOR
Intervention: Distilled water
Number of subjects: 20
Study 12059911 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0% sodium hypochlorite and 15% EDTAC (not instrumented)
Number of subjects: 20
Study 10530177 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% NaF solution rinsing (n = 49)
Number of subjects: 164
Study 10530177 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.66 mg NaF tablet (n = 51)
Number of subjects: 164
Study 10530177 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste slurry brushing (n = 32)
Number of subjects: 164
Study 10530177 — intervention group
Group type: COMPARATOR
Intervention: Usual brushing (n = 32)
Number of subjects: 164
Study 7862939 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum (chewed for 4 days)
Number of subjects: 0
Study 7862939 — intervention group
Group type: COMPARATOR
Intervention: Chronic smoking (smoked ad libitum for 2 days, then abstinent for 4 days, then resumed smoking for 2 days)
Number of subjects: 0
Study 2757958 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA) 5 mg/kg per day
Number of subjects: 17
Study 2757958 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA) continued for up to 4 weeks after clinical clearance
Number of subjects: 17
Study 2757958 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA)
Number of subjects: 17
Study 4817159 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test in the afternoon
Number of subjects: 31
Study 31479045 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited Sampling Strategies (LSS) with sampling at 0, 120, 180, and 240 minutes after the start of the second infusion (LSS15)
Number of subjects: 297
Study 31479045 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited Sampling Strategies (LSS)
Number of subjects: 297
Study 31479045 — intervention group
Group type: COMPARATOR
Intervention: Intensive Sampling Strategy (ISS)
Number of subjects: 297
Study 31206973 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment group
Number of subjects: 195
Study 31206973 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment group
Number of subjects: 195
Study 27780297 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg Nazolam
Number of subjects: 16
Study 27780297 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0 mg Nazolam
Number of subjects: 16
Study 27780297 — intervention group
Group type: COMPARATOR
Intervention: 2.5 mg intravenous midazolam
Number of subjects: 16
Study 27780297 — intervention group
Group type: EXPERIMENTAL
Intervention: Nazolam
Number of subjects: 16
Study 25855760 — intervention group
Group type: COMPARATOR
Intervention: OAC (standard triple therapy)
Number of subjects: 300
Study 25855760 — intervention group
Group type: EXPERIMENTAL
Intervention: OA-OACM (hybrid therapy)
Number of subjects: 300
Study 25855760 — intervention group
Group type: EXPERIMENTAL
Intervention: OACM (10 day concomitant regimen)
Number of subjects: 300
Study 24144653 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone sustained-release/bupropion sustained-release (NB)
Number of subjects: 505
Study 24144653 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 505
Study 21356537 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 months of case management by district nurses for both older adults and informal caregivers
Number of subjects: 99
Study 21356537 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 99
Study 18821000 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention activities (presentations at organizations)
Number of subjects: 591
Study 18821000 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 591
Study 18821000 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of or participation in intervention activities
Number of subjects: 591
Study 18821000 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 591
Study 17701410 — intervention group
Group type: EXPERIMENTAL
Intervention: Positron emission tomography (PET) scanning
Number of subjects: 186
Study 15253920 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training
Number of subjects: 301
Study 15253920 — intervention group
Group type: COMPARATOR
Intervention: No training (control)
Number of subjects: 301
Study 11547370 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-step lateral release sequence (PCL, IT band, PT/LCL, biceps femoris tendon)
Number of subjects: 14
Study 11547370 — intervention group
Group type: COMPARATOR
Intervention: 5-step lateral release sequence (PCL, posterolateral capsule, IT band, PT, LCL)
Number of subjects: 14
Study 11547370 — intervention group
Group type: EXPERIMENTAL
Intervention: Both sequences (4-step and 5-step)
Number of subjects: 14
Study 9565144 — intervention group
Group type: EXPERIMENTAL
Intervention: pFSH
Number of subjects: 20
Study 9565144 — intervention group
Group type: COMPARATOR
Intervention: GnRH-a plus pFSH
Number of subjects: 20
Study 7800954 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice daily oral theophylline (800 mg/day)
Number of subjects: 8
Study 7800954 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice daily inhaled budesonide (0.8 mg/day)
Number of subjects: 8
Study 31254097 — intervention group
Group type: EXPERIMENTAL
Intervention: Early discharge (≤ 48 hours)
Number of subjects: 311
Study 31254097 — intervention group
Group type: COMPARATOR
Intervention: Inpatient management (> 48 hours)
Number of subjects: 311
Study 29546857 — intervention group
Group type: EXPERIMENTAL
Intervention: H1-coil rTMS as an add-on to stable pharmacotherapy
Number of subjects: 228
Study 29546857 — intervention group
Group type: EXPERIMENTAL
Intervention: Figure-8-coil rTMS as an add-on to stable pharmacotherapy
Number of subjects: 228
Study 29546857 — intervention group
Group type: COMPARATOR
Intervention: Stable pharmacotherapy alone
Number of subjects: 228
Study 26662632 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant
Number of subjects: 324
Study 26662632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 324
Study 25911823 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Ganmai Dazao decoction
Number of subjects: 86
Study 25911823 — intervention group
Group type: COMPARATOR
Intervention: Deanxit (Control)
Number of subjects: 86
Study 22913800 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel (titrated to a maximum of 12 mg/day over 12 weeks, maintained for up to 424 weeks)
Number of subjects: 138
Study 20552369 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy (LA)
Number of subjects: 147
Study 20552369 — intervention group
Group type: COMPARATOR
Intervention: Open appendectomy (OA)
Number of subjects: 147
Study 18435373 — intervention group
Group type: EXPERIMENTAL
Intervention: Adper Scotchbond 2 (SB)
Number of subjects: 40
Study 18435373 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (SE)
Number of subjects: 40
Study 18435373 — intervention group
Group type: EXPERIMENTAL
Intervention: Adper Scotchbond MP (MP)
Number of subjects: 40
Study 18435373 — intervention group
Group type: EXPERIMENTAL
Intervention: Adper Prompt L-Pop (LP)
Number of subjects: 40
Study 16490027 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavernosal arteries diameter assessment
Number of subjects: 212
Study 16490027 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 212
Study 16490027 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachial arteries assessment
Number of subjects: 212
Study 14655913 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline (upward titration from 0.5 mg to 2 mg in a single evening dose)
Number of subjects: 12
Study 10731495 — intervention group
Group type: EXPERIMENTAL
Intervention: High-glycemic-index (high-GI) diet
Number of subjects: 10
Study 10731495 — intervention group
Group type: COMPARATOR
Intervention: Low-glycemic-index (low-GI) diet
Number of subjects: 10
Study 9363043 — intervention group
Group type: EXPERIMENTAL
Intervention: abecarnil
Number of subjects: 180
Study 9363043 — intervention group
Group type: EXPERIMENTAL
Intervention: alprazolam
Number of subjects: 180
Study 9363043 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 180
Study 1489150 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine aerosol
Number of subjects: 38
Study 1489150 — intervention group
Group type: COMPARATOR
Intervention: Saline aerosol (control)
Number of subjects: 38
Study 1489150 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% lidocaine aerosol
Number of subjects: 38
Study 3888102 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin small-particle aerosol treatment (2.4 g over 42 h during 68 h of hospitalization)
Number of subjects: 38
Study 3888102 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin aerosol treatment
Number of subjects: 38
Study 3888102 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 38
Study 31574097 — intervention group
Group type: EXPERIMENTAL
Intervention: Football group (FG) - 6 months of free-of-charge football training twice weekly
Number of subjects: 214
Study 31574097 — intervention group
Group type: EXPERIMENTAL
Intervention: Football group (FG)
Number of subjects: 214
Study 31574097 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (UG)
Number of subjects: 214
Study 30202187 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Engagement and Planning (CEP)
Number of subjects: 1013
Study 30202187 — intervention group
Group type: COMPARATOR
Intervention: Resources for Services (RS)
Number of subjects: 1013
Study 26204844 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium ranelate (SrR) 2 g daily
Number of subjects: 24
Study 26204844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 24247211 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose (40g)
Number of subjects: 16
Study 24247211 — intervention group
Group type: COMPARATOR
Intervention: Glucose (40g)
Number of subjects: 16
Study 24247211 — intervention group
Group type: EXPERIMENTAL
Intervention: Inulin (40g)
Number of subjects: 16
Study 24247211 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose + Fructose (40g each)
Number of subjects: 16
Study 22930293 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin vaginal cream (CVC) for three days
Number of subjects: 199
Study 22930293 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199
Study 22930293 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin vaginal cream (CVC) additional seven-day course
Number of subjects: 199
Study 22930293 — intervention group
Group type: COMPARATOR
Intervention: Placebo additional seven-day course
Number of subjects: 199
Study 22930293 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin vaginal cream (CVC) additional treatment
Number of subjects: 199
Study 22930293 — intervention group
Group type: COMPARATOR
Intervention: Placebo additional treatment
Number of subjects: 199
Study 22930293 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin vaginal cream (CVC)
Number of subjects: 199
Study 19429844 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety condition (induced by pictures from the International Affective Picture System and in sensu exposure to individual anxiety‐provoking situations)
Number of subjects: 90
Study 19429844 — intervention group
Group type: COMPARATOR
Intervention: Nonanxiety condition (neutral condition)
Number of subjects: 90
Study 17394957 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg 12 hours before PCI, with a further 40 mg preprocedure dose)
Number of subjects: 171
Study 17394957 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study 16227994 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoglobin S variant and alpha(+)-thalassemia inherited together
Number of subjects: 0
Study 16227994 — intervention group
Group type: COMPARATOR
Intervention: Hemoglobin S variant inherited alone
Number of subjects: 0
Study 16227994 — intervention group
Group type: COMPARATOR
Intervention: Alpha(+)-thalassemia inherited alone
Number of subjects: 0
Study 11861723 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar resurfacing
Number of subjects: 220
Study 11861723 — intervention group
Group type: COMPARATOR
Intervention: No patellar resurfacing
Number of subjects: 220
Study 10206312 — intervention group
Group type: EXPERIMENTAL
Intervention: High energy intake (> 12,013 kJ)
Number of subjects: 1378
Study 10206312 — intervention group
Group type: COMPARATOR
Intervention: Low energy intake (< 7004 kJ)
Number of subjects: 1378
Study 10206312 — intervention group
Group type: EXPERIMENTAL
Intervention: Tall girls (> 148.6 cm)
Number of subjects: 1378
Study 10206312 — intervention group
Group type: COMPARATOR
Intervention: Short girls (< 135.9 cm)
Number of subjects: 1378
Study 10206312 — intervention group
Group type: EXPERIMENTAL
Intervention: High Quetelet's index (QI, kg m(‐2)) (> 20.7)
Number of subjects: 1378
Study 10206312 — intervention group
Group type: COMPARATOR
Intervention: Low Quetelet's index (QI, kg m(‐2)) (< 16.1)
Number of subjects: 1378
Study 10206312 — intervention group
Group type: EXPERIMENTAL
Intervention: Hispanic, Asian/Pacific Island and African‐American girls
Number of subjects: 1378
Study 7606182 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 units of botulinum A toxin
Number of subjects: 23
Study 7606182 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 7606182 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin injections
Number of subjects: 23
Study 2350209 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine hydrochloride (40 mg intravenously)
Number of subjects: 8
Study 2350209 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 8
Study 111274 — intervention group
Group type: EXPERIMENTAL
Intervention: Clorgyline treatment for 4 weeks
Number of subjects: 16
Study 111274 — intervention group
Group type: COMPARATOR
Intervention: Pargyline treatment
Number of subjects: 16
Study 111274 — intervention group
Group type: EXPERIMENTAL
Intervention: Clorgyline in crossover study
Number of subjects: 16
Study 111274 — intervention group
Group type: COMPARATOR
Intervention: Pargyline in crossover study
Number of subjects: 16
Study 31863189 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine 30 mg intravenously after induction of general anesthesia
Number of subjects: 96
Study 31863189 — intervention group
Group type: COMPARATOR
Intervention: Normal saline 2 ml
Number of subjects: 96
Study 30504445 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (1000 mg single infusion)
Number of subjects: 81
Study 30504445 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 28879445 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoporosis and You knowledge scale
Number of subjects: 7749
Study 28879445 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 7749
Study 25533540 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole (PPX) 0.25 mg to 0.75 mg, taken 2-3 hours before bedtime for 12 weeks
Number of subjects: 204
Study 25533540 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole (PPX)
Number of subjects: 204
Study 25533540 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study 23676253 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 IU intranasal oxytocin
Number of subjects: 23
Study 23676253 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 21833787 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT Parents Raising Safe Kids program
Number of subjects: 0
Study 21833787 — intervention group
Group type: COMPARATOR
Intervention: Standard community‐based support services
Number of subjects: 0
Study 19415120 — intervention group
Group type: EXPERIMENTAL
Intervention: MB-artesunate (AS)
Number of subjects: 180
Study 19415120 — intervention group
Group type: EXPERIMENTAL
Intervention: MB-amodiaquine (AQ)
Number of subjects: 180
Study 19415120 — intervention group
Group type: COMPARATOR
Intervention: AS-amodiaquine (AQ)
Number of subjects: 180
Study 17268766 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous anesthesia
Number of subjects: 86
Study 17268766 — intervention group
Group type: COMPARATOR
Intervention: Epidural anesthesia
Number of subjects: 86
Study 17268766 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 86
Study 15354727 — intervention group
Group type: EXPERIMENTAL
Intervention: SUNY4001 (adenosine)
Number of subjects: 41
Study 15354727 — intervention group
Group type: COMPARATOR
Intervention: Exercise (ergometer)
Number of subjects: 41
Study 11146393 — intervention group
Group type: EXPERIMENTAL
Intervention: bivalent HAV/HBV vaccine
Number of subjects: 39
Study 11146393 — intervention group
Group type: COMPARATOR
Intervention: HBV vaccine alone
Number of subjects: 39
Study 9557092 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics and Gamma‐Venin P
Number of subjects: 30
Study 9557092 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics only
Number of subjects: 30
Study 8354633 — intervention group
Group type: EXPERIMENTAL
Intervention: AZT treatment
Number of subjects: 67
Study 8354633 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 67
Study 3524509 — intervention group
Group type: EXPERIMENTAL
Intervention: D-phenylalanine (DPA) 250 mg orally four times a day for four weeks
Number of subjects: 30
Study 3524509 — intervention group
Group type: COMPARATOR
Intervention: Lactose (placebo) orally four times a day for four weeks
Number of subjects: 30
Study 3524509 — intervention group
Group type: EXPERIMENTAL
Intervention: D-phenylalanine (DPA)
Number of subjects: 30